Free Access
Math. Model. Nat. Phenom.
Volume 7, Number 3, 2012
Page(s) 62 - 77
Published online 06 June 2012
  1. A. M. Arvin, A. A. Gershon. Live attenuated varicella vaccine. Ann. Rev. Microbiol., 50 (1996), 59–100. [CrossRef]
  2. A. M. Arvin, A. A. Gershon. Live attenuated varicella vaccine. Ann Rev Microbiol., 50 (1996), 59–100. [CrossRef]
  3. M. Brisson, W. J. Edmunds, N. J. Gay, B. Law, G. De Serres. Modelling the Impact of Immunization on the Epidemiology of Varicella Zoster Virus. Epidemiology and Infection, 125 (2000), 651–669. [CrossRef] [PubMed]
  4. CDC. Prevention of varicella : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, 56 (2007), No. RR4, OpenURL.
  5. Centers for Disease Control and Prevention. Prevention of varicella : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, 45 (1997), No. RR-11, 35–40.
  6. S. Deguen, A. Flahault. Impact on Immunization of Seasonal Cycle of Chickenpox. European Journal of Epidemiology, 16 (2000), 1177–1181. [CrossRef] [PubMed]
  7. O. Diekmann, J. A. P. Heesterbeek, J. A. J. Metz. On the definition and the computation of the basic reproduction ratio in models for infectious diseases in heterogeneous populations. Journal of Mathematical Biology, 28 (1990), No. 4, 365–382, Doi : 10.1007/BF00178324. [CrossRef] [MathSciNet] [PubMed]
  8. W. J. Edmunds, M. Brisson. The effect of vaccination on the epidemiology of varicella zoster virus. Journal of Infection, 44 (2002), 211–219. [CrossRef]
  9. J. E. Forde, B. Meeker. A model of varicella-zoster reactivation. Mathematical Biosciences and Engineering, 7 (2010), 765–777. [CrossRef] [MathSciNet]
  10. G. P. Garnett, N. M. Ferguson. Predicting the effect of varicella vaccine on subsequent cases of zoster and varicella. Rev. Med. Virol., 6 (1996), 151–161. [CrossRef] [PubMed]
  11. G. P. Garnett, B. T. Grenfell. The Epidemiology of Varicella-Zoster Virus Infections : The Influence of Varicella on the Prevalence of Herpes Zoster. Epidemiology and Infection, 108 (1992), 513–528. [CrossRef] [PubMed]
  12. S. Hambleton, S. P. Steinberg, P. S. La Russa, E. D. Shapiro, A. A. Gershon. Risk of Herpes Zoster in adults immunized with varicella vaccine. J. Infect. Dis., 197 (2008), S196–199. [CrossRef] [PubMed]
  13. R. E. Hope-Simpson. The nature of herpes zoster : a long term study and a new hypothesis. Proc. Roy. Soc. Med., 58 (1965), 9–20.
  14. J. Hornberger, K. Robertus. Cost-Effectiveness of a Vaccine To Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Ann Intern Med., 145 (2006), 317–325. [PubMed]
  15. M. Karhunen, T. Leino, H. Salo, I. Davidkin, T. Kilpi, K. Auranen. Modelling the impact of varicella vaccination on varicella and zoster. Epidemiol Infect., 138 (2010), No. 4, 469–481. [CrossRef] [PubMed]
  16. M. N. Oxman, M. J. Levin, G. R. Johnson, K. E. Schmader, S. E. Straus, L. D. Gelb, R. D. Arbeit, M. S. Simberkoff, A. A. Gershon, L. E. Davis, A. Weinberg, K. D. Boardman, H. M. Williams, J. Hongyuan Zhang, P. N. Peduzzi, C. E. Beisel, V. A. Morrison, J. C. Guatelli, P. A. Brooks, C. A. Kauffman, C. T. Pachucki, K. M. Neuzil, R. F. Betts, P. F. Wright, M. R. Griffin, P. Brunell, N. E. Soto, A. R. Marques, S. K. Keay, R. P. Goodman, D. J. Cotton, J. W. Gnann, Jr., J. Loutit, M. Holodniy, W. A. Keitel, G. E. Crawford, S.-S. Yeh, Z. Lobo, J. F. Toney, R. N. Greenberg, P. M. Keller, R. Harbecke, A. R. Hayward, M. R. Irwin, T. C. Kyriakides, C. Y. Chan, I. S. F. Chan, W. W. B. Wang, P. W. Annunziato, J. L. Silber. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med., 352 (2005), No. 22, 2271–2284. [CrossRef] [PubMed]
  17. M. N. Oxman, M.J. Levin. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis., 197 (2008), Suppl. 2, S228–5236. [CrossRef] [PubMed]
  18. M. Socan, N. Berginc, J. Lajovic. Varicella susceptibility and transmission dynamics in Slovenia. BMC Public Health, 10 :360 (2010), 1–6. [CrossRef] [PubMed]
  19. M. C. Schuette, H. W. Hethcote. Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles. Bull Math Biol., 61 (1999), No. 6, 1031–1064. [CrossRef] [PubMed]
  20. G. Soldato. Nuove strategie preventive vaccinali : vantaggi e limiti del vaccino antivaricella (New preventive vaccine strategies : advantages and limits of the vaccine against chickenpox). Thesis (Advisor Prof. C. Granchelli), University “G. D’Annunzio” of Chieti-Pescara, Italy, 2005.
  21. N. Thiry, P. Beutels, F. Tancredi, L. Romanò, A. Zanetti, P. Bonanni, G. Gabutti, P. Van Damme. An economic evaluation of varicella vaccination in italian adolescents. Vaccine 22, (2004), 27-28, 3546–3562. [CrossRef]
  22. A. J. van Hoek, N. Gay, W. Opstelten, W. J. Edmunds. Estimating the cost-effectiveness of vaccination against Herpes Zoster in England and Wales. Vaccine, 27 (2009), No. 9, 1454–1467. [CrossRef] [PubMed]
  23. A. J. Van Hoek, A. Melegaro, E. W. Zaghenid, J. Edmunds, N. Gay. Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England. Vaccine, 29 (2011), 2411–2420. [CrossRef] [PubMed]
  24. M. Wharton. The epidemiology of varicella-zoster virus infections. Infect Dis Clinics N Am, 10 (1996), 571–581. [CrossRef]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.